Eosinophilic asthma is now recognized as an important subphenotype of asthma based on the pattern of inflammatory cellular infiltrate in the airway. Eosinophilic asthma can be associated with increased asthma severity, atopy, late-onset disease, and steroid refractoriness. Induced sputum cell count is the gold standard for identifying eosinophilic inflammation in asthma although several noninvasive biomarkers, including fractional exhaled nitric oxide and periostin, are emerging as potential surrogates. As novel therapies and biologic agents become increasingly available, there is an increased need for specific phenotype-directed treatment strategies. Greater recognition and understanding of the unique immunopathology of this asthma phenotype has important implications for management of the disease and the potential to improve patient outcomes. The present review provides a summary of the clinical features, pathogenesis, diagnosis, and management of eosinophilic asthma. © 2014 Walford and Doherty.
CITATION STYLE
Walford, H. H., & Doherty, T. A. (2014, April 11). Diagnosis and management of eosinophilic asthma: A US perspective. Journal of Asthma and Allergy. Dove Medical Press Ltd. https://doi.org/10.2147/JAA.S39119
Mendeley helps you to discover research relevant for your work.